

Amendment to the Claims

1. (canceled)
2. (currently amended) 4-{[1-(~~a~~Aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof.
3. (currently amended) 4-{[1-(~~a~~Aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide.

Claims 4–5 (canceled).

6. (Previously presented) A salt as claimed in claim 2, wherein the pharmaceutically acceptable acid addition salt has been formed by combination of 4-{[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide with a pharmaceutically acceptable acid having a pKa of 1.5 or less.
7. (Previously presented) A salt as claimed in claim 2, wherein the pharmaceutically acceptable acid addition salt of the 4-{[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide comprises a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, p-toluenesulfonate, benzenesulfonate, methanesulfonate, ethanesulfonate, or naphthalenesulfonate salt thereof.
8. (currently amended) 4-{[1-(~~a~~Aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide hydrochloride.

9. – 12.)Canceled)

13–25 (Canceled).

26. (original) A pharmaceutical composition comprising 4-{[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers and/or excipients.
27. (original) A pharmaceutical composition as claimed in claim 26, which is suitable for external topical administration to a human.

Claims 28–34 (canceled).

35. A pharmaceutical composition as claimed in claim 27, which is an ointment comprising:

- 4-{[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof present at 0.1% to 3% w/w;
- an oil phase (oily ointment base) present at 25% to 99% w/w;
- one or more surfactants present in total at 0.5% to 10% w/w; and

- one or more agents acting as a skin-penetration enhancer present in total at 0.5% to 50% w/w.

36. A pharmaceutical composition as claimed in claim 35, which is an ointment comprising:

- 4- {[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof present at 0.2% to 1.5% w/w;
 - an oil phase (oily ointment base) present at 50% to 80% w/w, and comprising white petrolatum present at 45 to 75% w/w, and also comprising mineral oil present at 2.5% to 15% w/w;
 - one or more surfactants present in total at 3% to 10% w/w; and
 - one or more hydrophilic agents acting as both a solubiliser and skin-penetration enhancer, present in total at 5% to 50% w/w;
- wherein, in the ointment composition, the oil phase (oily ointment base) and the hydrophilic solubiliser/penetration-enhancer phase have been emulsified to form an ointment emulsion.

37. A pharmaceutical composition as claimed in claim 27, which is a water-in-oil cream comprising:

- 4- {[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof present at 0.1% to 3% w/w;
- an oil phase (oily ointment base) present at 25% to 85% w/w;
- water present in 2% to 30% w/w;
- one or more surfactants present in total at 0.5% to 12% w/w; and
- one or more agents acting as a skin-penetration enhancer present in total at 0.5% to 50% w/w.

38. A pharmaceutical composition as claimed in claim 37, which is a water-in-oil cream emulsion comprising:

- 4- {[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof present at 0.2% to 1.5% w/w;
- an oil phase (oily ointment base) present at 35% to 70% w/w, and comprising white petrolatum present at 30% to 65% w/w, and also comprising mineral oil present at 2.5% to 15% w/w;
- water present in 5% to 25% w/w;
- one or more surfactants present in total at 3% to 10% w/w; and
- one or more hydrophilic agents acting as both a solubiliser and skin-penetration enhancer, present in total at 5% to 50% w/w.

39. A pharmaceutical composition as claimed in claim 27, which is an oil-in-water cream comprising:

- 4- {[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof present at 0.1% to 3% w/w;
- an oil phase (oily ointment base) containing one or more ingredients capable of acting as emollients, the oil phase being present at 20% to 60% w/w;
- water present in 15% to 75% w/w;
- one or more surfactants present in total at 0.5% to 12% w/w; and

- one or more agents acting as a skin-penetration enhancer, present in total at 0.5% to 50% w/w.

40. A pharmaceutical composition as claimed in claim 39, which is an oil-in-water cream emulsion comprising:

- 4- {[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof present at 0.2% to 3% w/w;
- an oil phase (oily ointment base) containing one or more ingredients capable of acting as emollients, the oil phase being present at 30% to 55% w/w;
- water present in 15% to 50% w/w;
- one or more surfactants present in total at 3% to 10% w/w; and
- one or more hydrophilic agents acting as both a solubiliser and skin-penetration enhancer, present in total at 5% to 50% w/w;

wherein the oil phase comprises mineral oil present at 20% to 45% w/w, and/or comprises microcrystalline wax present at 5% to 25% w/w, and/or comprises a silicone present at 0.5% to 10% w/w.

41. (currently amended) A method for the treatment and/or prophylaxis of ~~an inflammatory and/or allergic disease~~ atopic dermatitis in a ~~mammal~~ patient comprising administering a therapeutically effective amount of 4- {[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof alone, or in admixture with a pharmaceutically acceptable excipient.

42. (cancelled)